TSC-203-A0201 + TSC-201-B0702

TSC-203-A0201 + TSC-201-B0702 is a combination of two autologous, engineered T cell receptor (TCR)-T cell therapies developed by TScan Therapeutics for the treatment of solid tumors. Each component targets a distinct tumor-associated antigen presented by specific HLA molecules. TSC-203-A0201 is a putative autologous, participant-derived engineered TCR-T therapy targeting PReferentially expressed Antigen in Melanoma (PRAME) presented on HLA-A*02:01. PRAME is highly expressed in melanomas and various other solid tumors, including head & neck cancers and non-small cell lung cancers[4][6][7][8]. TSC-201-B0702 is an autologous engineered TCR-T therapy targeting MAGEC2 (MAGE family member C2) presented on HLA-B*07:02[1]. Both products are designed to be used as part of multiplexed or combination cellular immunotherapy regimens to address tumor heterogeneity and immune escape mechanisms[2][5]. The combination is currently being evaluated in Phase 1 clinical trials for multiple HPV-related and other solid tumors.